| Leslie J Havard, MD | |
|
1353 Paseo Del Pueblo Sur Ste D, Taos, NM 87571-5958 | |
| (575) 613-8090 | |
| Not Available |
| Full Name | Leslie J Havard |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 33 Years |
| Location | 1353 Paseo Del Pueblo Sur Ste D, Taos, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891803920 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 37215 (Colorado) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Epiphany Dermatology Of New Mexico, Llc | 4082919691 | 23 |
News Archive
RAD Technology Medical Systems LLC in conjunction with BREASTCANCER.ORG announced a unique awareness campaign that will start this week with the transit of the first Temporary Radiotherapy Vault. RAD has pioneered patented designs for radiotherapy vaults and clinics.
Medicsight PLC has announced the submission of a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for clearance to market its ColonCAD(TM) image analysis software throughout the U.S.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.
A collaborative network that aims to put the Yorkshire and Humber region at the forefront of the development of product formulations to improve everyday products is being launched in Leeds.
› Verified 6 days ago
| Entity Name | Epiphany Dermatology Of New Mexico, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447615760 PECOS PAC ID: 4082919691 Enrollment ID: O20160219000201 |
News Archive
RAD Technology Medical Systems LLC in conjunction with BREASTCANCER.ORG announced a unique awareness campaign that will start this week with the transit of the first Temporary Radiotherapy Vault. RAD has pioneered patented designs for radiotherapy vaults and clinics.
Medicsight PLC has announced the submission of a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for clearance to market its ColonCAD(TM) image analysis software throughout the U.S.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.
A collaborative network that aims to put the Yorkshire and Humber region at the forefront of the development of product formulations to improve everyday products is being launched in Leeds.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leslie J Havard, MD 7300 Ranch Road 2222, Bldg 1, Ste 200, Austin, TX 78730-3255 Ph: (512) 759-8932 | Leslie J Havard, MD 1353 Paseo Del Pueblo Sur Ste D, Taos, NM 87571-5958 Ph: (575) 613-8090 |
News Archive
RAD Technology Medical Systems LLC in conjunction with BREASTCANCER.ORG announced a unique awareness campaign that will start this week with the transit of the first Temporary Radiotherapy Vault. RAD has pioneered patented designs for radiotherapy vaults and clinics.
Medicsight PLC has announced the submission of a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for clearance to market its ColonCAD(TM) image analysis software throughout the U.S.
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.
A collaborative network that aims to put the Yorkshire and Humber region at the forefront of the development of product formulations to improve everyday products is being launched in Leeds.
› Verified 6 days ago
Lauren M Good, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1399 Weimer Rd, #600, Taos, NM 87571 Phone: 575-758-9519 |